Catalan Institute of Oncology (ICO)
If you are the contact person for this centre and you wish to make any changes, please contact us.
Research technician at the Girona Cancer Epidemiology and Registry Unit of the Catalan Institute of Oncology-Oncology Master Plan
Deputy Head of the Tobacco Control Unit at the Catalan Institute of Oncology and lecturer in the Department of Nursing, Public Health, Mental Health and Maternal and Child Health at the University of Barcelona
Medical Oncologist at the Catalan Institute of Oncology (ICO
Assistant doctor of medical oncology at the Catalan Institute of Oncology and at the Girona University Hospital Doctor Josep Trueta
Director of Epidemiology, Prevention and Cancer Control at the Catalan Institute of Oncology and Director of the WHO Collaborating Centre for Tobacco Control at the Catalan Institute of Oncology
Head of the Haematology Department at ICO Badalona
Principal investigator, Digital Health Programme ICOnnecta't, and member of the Group of Psycho-oncology and Digital Health at IDIBELL
Epidemiologist at the Girona Cancer Epidemiology and Registry Unit of the Catalan Institute of Oncology - Oncology Master Plan
Head of the Medical Oncology Service at the Catalan Institute of Oncology in l'Hospitalet (ICO)
Principal Investigator of the Nutrition and Cancer Unit of the Catalan Institute of Oncology (ICO) and the Bellvitge Biomedical Research Institute (IDIBELL)

Research involving more than 200 patients with depression, whose symptoms had not improved after NHS talk therapy shows that those who took part in eight group sessions of mindfulness-based cognitive therapy saw their depressive symptoms reduced, compared with those who received treatment as usual. The study is published in The Lancet Psychiatry.

A team led by the Spanish National Cancer Research Centre (CNIO) has shown in mice that a high-fat diet increases metastasis in triple-negative breast cancer, which has the worst prognosis. In addition, it has identified several of the mechanisms that would explain this, such as the activation of platelets and coagulation, which would help the tumour hide from the body's defences and prepare the so-called ‘pre-metastatic niche’. According to the researchers, who published the results in Nature Communications, ‘this mechanism could be extrapolated to other tumour types and other organs’. The results suggest that ‘dietary intervention, together with the control of platelet activity, may increase the efficiency of certain anti-tumour treatments’.

In women, high consumption of sugary drinks is associated with an increased risk of oral cavity cancer, according to a study published in JAMA Otolaryngology-Head & Neck Surgery. Among research participants who consumed one or more sugary drinks per day, the rate of these cancers was 5 cases per 100,000 people, compared to 2 cases per 100,000 among those who drank less than one per month. The analysis is based on data from more than 162,000 nurses followed for 30 years in the United States. According to the authors, further studies with larger samples, including men, are needed to validate these results.

An international team has found that aspirin is capable of reducing the appearance of metastasis in mice, by enabling the activation of T lymphocytes capable of recognising tumour cells. The research showed that several different mouse cancer models — including breast cancer, colon cancer and melanoma — treated with aspirin showed a lower rate of metastasis in other organs, such as the lungs and liver, compared to untreated mice. According to the authors, who publish the results in the journal Nature, ‘the finding paves the way for the use of more effective anti-metastatic immunotherapies’.

A paper published in The Lancet Respiratory Medicine has analyzed new cases of lung cancer worldwide during the year 2022. While the incidence in women continues to approach that of men, the decrease in tobacco consumption in many countries causes the proportion of cases in non-smokers to increase. This increase is associated with air pollution, especially in countries such as China.

A team of researchers has analyzed data from the World Health Organization to estimate the incidence of colorectal cancer in 50 countries around the world. Their conclusions, based on records up to 2017, are that in most high-income countries its incidence continues to increase in young people (under 50 years of age). This increase, however, is not observed in Spain. The results are published in the journal The Lancet Oncology.

Despite considerable advances in the discovery and development of new cancer drugs, there are significant disparities in both the availability and timeliness of these medicines around the world, with the poorest countries being left out, according to an analysis published in the journal BMJ Global Health. According to the study, few new cancer drugs were launched in low- and lower-middle-income countries, and the gap between rich and poor countries widened over the three decades between 1990 and 2022.

Prostate cancer screening tests using PSA (Prostate Specific Antigen) are associated with overdiagnosis, which calls into question their use. A clinical trial in men aged 50-60 years published in the journal NEJM has studied the possibility of adding an MRI test in those with an elevated PSA level and dispensing with biopsy if imaging finds no suspicious lesions. The results indicate that the procedure avoids more than half of clinically irrelevant cancer diagnoses that would not need treatment and only slightly increases the risk of failing to identify those that may become incurable. The authors recommend, on the basis of the study, to review the recommendations for such screening.

A study has analyzed data on prostate cancer incidence and mortality in 26 countries in Europe between 1980 and 2020. Its findings are that new diagnoses have increased due to the widespread use of PSA [prostate-specific antigen] testing, but mortality rates have not benefited in parallel. This suggests possible overdiagnosis, i.e., the detection of harmless tumors that are unlikely to cause symptoms or death in the patient's lifetime. The results are published in the journal The BMJ.

The sperm of men infected with high-risk genotypes of the human papillomavirus (HPV) suffers more damage from oxidative stress and has a weaker immune response, which can lead to reduced fertility. This is one of the conclusions of a study published in the journal Frontiers in Cellular and Infection Microbiology. The research compared the semen of 20 adults infected with high-risk genotypes, seven infected with low-risk genotypes, and 43 adults without infections.